COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Ivermectin study #59 of 90
1/19 Late treatment study
Rezai et al., IRCT20111224008507N3 (Preprint)
Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020
Source   PDF   Share   Tweet
RCT in Iran showing shorter time to clinical recovery with Ivermectin.
Results are from: [1]
Trial details: [2] (double blind according to the trial registration)

Rezai et al., 1/19/2021, Double Blind Randomized Controlled Trial, Iran, Middle East, preprint, 1 author, dosage 200μg/kg single dose.
recovery time, 21.2% lower, relative time 0.79, p = 0.02, treatment 51, control 52.
hospitalization time, 17.9% lower, relative time 0.82, p = 0.01, treatment 51, control 52.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 90 studies    Meta analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Submit